{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chilblains/management/management/","result":{"pageContext":{"chapter":{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 9cb4cc62-27d2-4791-bb34-181ceea2c96f --><h2>Scenario: Management of chilblains</h2><!-- end field 9cb4cc62-27d2-4791-bb34-181ceea2c96f -->","summary":"Covers the management of people with chilblains.","htmlStringContent":"<!-- begin item 517debb5-f6fa-4987-acb0-391a7cf25818 --><!-- begin field a4b2e2ac-ea87-4639-8534-acbc01572839 --><p>From age 1 month onwards.</p><!-- end field a4b2e2ac-ea87-4639-8534-acbc01572839 --><!-- end item 517debb5-f6fa-4987-acb0-391a7cf25818 -->","topic":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92","topicId":"17adddaf-c9b6-4278-9b49-932d14f56439","topicName":"Chilblains","slug":"chilblains","lastRevised":"Last revised in June 2018","chapters":[{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6b34a51-a690-5858-9a53-0dc5d5b0e608","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5f3bae74-0385-5bf1-b250-9e74f16cfe18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4ae9419d-bc20-56ba-91a1-0420a339c087","slug":"changes","fullItemName":"Changes"},{"id":"e57dda70-8cbd-58d2-a2fb-8901c08e6853","slug":"update","fullItemName":"Update"}]},{"id":"ddec423e-57a6-54df-ba06-4014b41b839c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9315120c-762a-5273-867b-759b5537e4b8","slug":"goals","fullItemName":"Goals"},{"id":"666bca6f-0132-53bc-95cc-27fcbd0b4a96","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8b7e8a8e-c9dd-5555-8409-dfea005ea395","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fa795717-6d81-577e-b792-90e487b3895c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bff6f393-7347-51fa-8d46-95b80a272b9e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7da4aff5-e153-5f3f-bc51-0a943110c08d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1cc6d520-d1d7-5bcd-9d7c-b1352c82d453","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bba6260f-6b68-52b5-88c0-17f3ba449705","slug":"definition","fullItemName":"Definition"},{"id":"f4b6f42f-60f1-56db-9cc2-c9d377ec6c5a","slug":"causes","fullItemName":"Causes"},{"id":"adb617b9-5304-53c4-8f1f-6aaec8a9c35b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16008222-9ac8-5d8e-9380-55d21f8ca4d9","slug":"complications","fullItemName":"Complications"},{"id":"16a3612e-723d-580a-a4c7-157274078ba8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08c8ac64-d612-5dfe-9926-2d0dfbc02f14","slug":"assessment","fullItemName":"Assessment"},{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","fullItemName":"Management","slug":"management","subChapters":[{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"c98234ab-a54f-5b11-bd3d-ddc791a382d6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c4fbb70-40dc-5931-9e8e-6d8fdcd80db4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a6193060-7713-5e53-9336-66e3cb961a3a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1d12d25-39b2-5827-a25e-dcf5536bf470","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"435de6c9-1336-5c37-8c94-8ab2ee7f2adb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cc4fe9b8-3554-5630-88cd-6dfee9d06235","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d1b809a-3a66-5daa-a184-7cdfb748fe77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d01450d0-bab3-5fff-9ec6-40623a484024","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d1673e66-b9f8-5e57-82d2-75b660a76f9f","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field e4c75413-e639-440f-9186-b6c0e8b4c3ef --><h3>How should I manage a person with chilblains?</h3><!-- end field e4c75413-e639-440f-9186-b6c0e8b4c3ef -->","summary":null,"htmlStringContent":"<!-- begin item 86afd377-18c0-4685-a525-dd120a1d7d82 --><!-- begin field e303f782-6659-4a5e-9319-871d739de030 --><ul><li><strong>Explain the diagnosis and provide patient information </strong>— patient information is available from:<ul><li><a data-hyperlink-id=\"dccd60f0-fc78-441b-aee6-a90b00c83866\" href=\"http://www.nhs.uk/\" target=\"_blank\">NHS </a><a href=\"https://www.nhs.uk/conditions/\" data-hyperlink-id=\"b8614614-2356-4ca2-9fef-aa5600ac1655\">A-Z</a> — <a data-hyperlink-id=\"8c9246ca-4938-4c6f-8ed1-a90b00c83881\" href=\"https://www.nhs.uk/conditions/chilblains/\" target=\"_blank\">Chilblains</a>.</li></ul></li><li><strong>If an <a class=\"topic-reference internal-reference\" href=\"/topics/chilblains/background-information/causes/\">underlying condition</a> (such as lupus erythematosus or a haematological disorder) is suspected:</strong><ul><li>Arrange further investigations/refer to a specialist depending on the specific clinical situation.</li></ul></li><li><strong>If chilblains are thought to be idiopathic:</strong><ul><li>Reassure the person that the condition is usually self-limiting and should resolve within 2–3 weeks.</li><li>Advise the person on self-care measures including:<ul><li>Drying and gradually warming the skin — application of direct heat should be avoided.</li><li>Avoidance of smoking, if relevant — for further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking Cessation</a>.</li></ul></li><li>Advise the person on preventative measures to prevent recurrent episodes including:<ul><li>Avoidance of cold, damp conditions if possible.</li><li>Wearing adequate clothing including warm gloves and socks.</li><li>Avoidance of drugs that may cause blood vessel constriction such as caffeine and decongestants.</li><li>Avoidance of smoking, if relevant — for further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking Cessation</a>.</li></ul></li><li>Do not routinely offer drug treatment.</li></ul></li><li><strong>If chilblains are severe, chronic and do not respond to appropriate self-care measures:</strong><ul><li>Reassess the person and reconsider the possible <a class=\"topic-reference internal-reference\" href=\"/topics/chilblains/background-information/causes/\">underlying causes</a> and the diagnosis.<ul><li>If an underlying condition (such as lupus erythematosus) is suspected arrange further investigations/refer to a specialist depending on the specific clinical situation.</li><li>Discuss with/refer to a specialist if the diagnosis is uncertain.</li></ul></li><li>Seek specialist advice if conservative measures fail in children, pregnant or breastfeeding women.</li><li>If no underlying cause can be identified and there are no contraindications, consider prescribing modified-release nifedipine 20-60mg daily (off-label indication).<ul><li>Titrate slowly up to a maximum dose of 60 mg daily depending on response and tolerability.</li><li>Monitor the person's blood pressure as nifedipine may be associated with hypotension.</li><li>Discontinue treatment if not tolerated or response is inadequate.</li><li>Continue treatment until the lesions have healed, or for the rest of the cold season if prophylaxis is indicated.</li><li>Seek specialist advice if nifedipine is unsuitable or not tolerated.</li><li>Do <em>not</em> prescribe nifedipine to children under the age of 18 years or pregnant or breastfeeding women.</li></ul></li><li>Advise continuation of self-care and preventative measures in addition to drug treatment.</li></ul></li></ul><!-- end field e303f782-6659-4a5e-9319-871d739de030 --><!-- end item 86afd377-18c0-4685-a525-dd120a1d7d82 -->","subChapters":[{"id":"fe3e7cc4-ac13-58b8-957b-3a1b5696366a","slug":"basis-for-recommendation-829","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d99c5b62-8620-4962-b31d-a90300d0d51d --><h4>Basis for recommendation</h4><!-- end field d99c5b62-8620-4962-b31d-a90300d0d51d -->","summary":null,"htmlStringContent":"<!-- begin item 829e1ade-ddf9-4af2-9ae7-a90300d0d30e --><!-- begin field 28a5525b-b2b3-4578-8d96-a90300d0d51d --><p>The recommendations on the management of chilblains are based on the clinical guideline <em>Perniosis (syn. Chilblains)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>] and expert opinion in Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Cappel, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Gordon, 2014</a>].</p><h5>Conservative measures</h5><ul><li>Expert opinion in the Primary Care Dermatological Society guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>], Rook’s textbook of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Cappel, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Gordon, 2014</a>] is that conservative measures (such as keeping the area warm, avoidance of cold, damp conditions and stopping smoking) are the mainstay of treatment in chilblains. Most chilblains are self-limiting and resolve within 2-3 weeks.</li></ul><h5>Drug treatment is not generally recommended</h5><ul><li>Routine drug treatment and prophylaxis for chilblains is not recommended by CKS because:<ul><li>The condition is self-limiting and generally resolves within 2-3 weeks with appropriate self-care measures. These measures are also helpful in preventing recurrence.</li><li>The evidence for drug treatment is poor (see below) and does not support its routine use in people with chilblains.</li></ul></li></ul><h5>Use of nifedipine for severe or persistent chilblains</h5><ul><li>Many sources recommend the use of nifedipine in treatment and prevention of chilblains if conservative measures fail but available evidence is based on a limited number of small trials and conflicts between studies:<ul><li>Expert opinion in the Primary Care Dermatological Society guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>], Rook’s textbook of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Gordon, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Cappel, 2014</a>] is that nifedipine can be considered if conservative measures have failed and chilblains are severe and persistent.</li><li>Expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2011</a>] quote evidence in favour of nifedipine (20 mg/day) over placebo from a small (n=10) double-blinded randomised controlled trial [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Rustin et al, 1989</a>].</li><li>A more recent randomized, placebo-controlled, double-blind, crossover trial (n=32 with chronic chilblains) found that nifedipine was not superior to placebo for treating chronic chilblains (p=0.44 in favour of nifedipine for patient reported symptoms and p=0.75 in favour of placebo for patient reported disability). In addition nifedipine was associated with a lower systolic blood pressure and a higher incidence of oedema. The author concludes that these findings do not support routine use of nifedipine for chronic chilblains [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2016</a>].</li></ul></li></ul><h5>Dosage of nifedipine</h5><ul><li>The PCDS clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>] and Rook’s textbook of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] do not specify a treatment dose of nifedipine.</li><li>The suggested nifedipine dose (off-label use) reflects that quoted in studies on nifedipine for the treatment and prevention of chilblains as well as published expert opinion and case reports [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Leger and Boccalon, 1997</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Parlette, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Jordaan, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Almahameed and Pinto, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Cappel, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Gordon, 2014</a>].</li></ul><h5>Do not prescribe nifedipine to children or women who are pregnant or breastfeeding</h5><ul><li>CKS recommends seeking specialist advice for these groups if conservative measures have failed as there is no evidence to support drug treatment in these groups.</li><li>Nifedipine is not licensed for use in children for any indication and is not suitable for women who are pregnant (contraindicated) or breastfeeding (safety data are lacking).</li></ul><!-- end field 28a5525b-b2b3-4578-8d96-a90300d0d51d --><!-- end item 829e1ade-ddf9-4af2-9ae7-a90300d0d30e -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}